Dogwood director granted 16,800 stock options

Dogwood Therapeutics director Richard James Whitley received a grant of stock options for 16,800 shares of Common Stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Dogwood Therapeutics director Richard James Whitley received a grant of stock options for 16,800 shares of Common Stock. The options carry an exercise price of $1.50 per share, become exercisable on June 16, 2027, and expire on June 16, 2036. Following this award, he holds 16,800 derivative securities directly.

Insider Trade Summary

Grant/Award: 16,800 shares

Grant/Award 1 txn

Insider Whitley Richard James

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	16,800	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 16,800 contracts (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dogwood Therapeutics (DWTX) report for Richard James Whitley?

Dogwood Therapeutics reported that director Richard James Whitley received a grant of 16,800 stock options. These options give him the right to buy Common Stock at a fixed price, reflecting equity-based compensation rather than an open-market share purchase or sale.

How many Dogwood Therapeutics (DWTX) shares are covered by the new stock options?

The new stock option award covers 16,800 shares of Dogwood Therapeutics Common Stock. Each option corresponds to one underlying share, so exercising all options would allow purchase of 16,800 shares at the preset exercise price stated in the filing.

What is the exercise price on Richard Whitley’s Dogwood Therapeutics (DWTX) options?

The options granted to Richard Whitley have an exercise price of $1.50 per share. This means he can buy Dogwood Therapeutics Common Stock at $1.50 for each option exercised, regardless of the market price when he chooses to exercise.

When can the new Dogwood Therapeutics (DWTX) stock options be exercised?

The filing states the stock options become exercisable on June 16, 2027. After that exercise date, Richard Whitley may choose to convert his options into shares at the $1.50 exercise price, any time before the options’ stated expiration date.

When do Richard Whitley’s Dogwood Therapeutics (DWTX) options expire?

The stock options awarded to Richard Whitley expire on June 16, 2036. If he does not exercise them by that expiration date, the options will lapse and no longer provide the right to purchase Dogwood Therapeutics Common Stock at the fixed exercise price.

Is this Dogwood Therapeutics (DWTX) Form 4 a market buy or sell of shares?

This Form 4 reports a grant of stock options, not a market trade. It is classified as a grant or award acquisition, meaning the director received derivative securities as compensation rather than buying or selling Common Stock on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/17/2026 - 01:17 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Whitley Richard James

(Last)

(First)

(Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA

GEORGIA

30009

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$1.5	06/16/2026		A		16,800		06/16/2027	06/16/2036	Common Stock	16,800	$0	16,800	D

Explanation of Responses:

	/s/ Greg Duncan, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR